# Advancing vaccine-based immunotherapy in glioblastoma treatment

## TL;DR

This paper reviews recent developments in using vaccines as immunotherapy for treating glioblastoma, a highly aggressive brain cancer.

## Contribution

The paper highlights recent advancements in vaccine-based immunotherapy, such as peptide and dendritic cell vaccines, for glioblastoma.

## Key findings

- Current treatments for glioblastoma, including surgery and chemotherapy, have limited success due to recurrence and resistance.
- Immunotherapy, particularly tumor vaccines, shows promise but faces challenges in clinical trial effectiveness.
- Peptide-based and cell-based vaccines are emerging as significant advancements in glioblastoma treatment.

## Abstract

Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers. Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical trials. This article reviews recent developments in vaccine-based immunotherapy for glioblastoma treatment.

Graphical Abstract